Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Stephen M AnsellJohn RadfordJoseph M ConnorsMonika Długosz-DaneckaWon-Seog KimAndrea GallaminiRadhakrishnan RamchandrenJonathan W FriedbergRanjana AdvaniMartin HutchingsAndrew M EvensPiotr SmolewskiKerry J SavageNancy L BartlettHyeon-Seok EomJeremy S AbramsonCassie DongFrank CampanaKeenan FentonMarkus PuhlmannDavid J Strausnull null

Published in: The New England journal of medicine (2022)

Patients who received A+AVD for the treatment of stage III or IV Hodgkin's lymphoma had a survival advantage over those who received ABVD. (Funded by Takeda Development Center Americas and Seagen; ECHELON-1 ClinicalTrials.gov number, NCT01712490; EudraCT number, 2011-005450-60.).

Keyphrases

hodgkin lymphoma
diffuse large b cell lymphoma
free survival
combination therapy
smoking cessation